FDA clears Theradaptive’s OASIS pivotal trial as spinal fusion graft race enters a new phase
Spine biologics has long lacked fresh competition. Theradaptive’s OsteoAdapt SP trial could test whether that market is ready to move.
Why Theradaptive’s OsteoAdapt could disrupt the $2bn spinal biologics market in 2026
ATEC secures U.S. rights to Theradaptive’s OsteoAdapt. Find out what this deal changes for spinal biologics in 2026 and beyond.
Inside Xtant Medical’s Strata launch: What sets it apart from legacy bone grafts
Xtant Medical Holdings, Inc. has launched its next-generation synthetic bone graft, nanOss Strata, in the United States. The graft, built from hydroxycarbonapatite (HCA), is designed to enhance bioactivity and integration in orthopedic and spinal surgeries. This launch follows the company’s strategic exit from non-core spinal implant assets, signaling a renewed focus on its biologics portfolio. […]